Latest News
Mandar Muzumdar, MD (left), and Siyuan "Steven" Wang, PhD, both associate professors of genetics, received an R33 award through the National Cancer Institute’s (NCI) Innovative Molecular Analysis Technologies program, which supports the development of novel technologies for cancer research.
- August 29, 2026Source: WTNH (With Jeremy Jacox, MD, PhD)
The Food and Drug Administration (FDA) has approved a first-of-its-kind pancreatic cancer drug. It’s a daily pill called Rasonque. This offers a new approach to treating the deadly illness. Dr. Jeremy Jacox of Yale School of Medicine and Yale Cancer Center offered insight on what makes the drug stand out, how it can pave the way for more cancer treatments, the high cost of the drug, and why pancreatic cancer is so much deadlier than other cancers.
- August 03, 2026Source: WTNH (w/ Mandar Muzumdar, MD)
In today’s Yale Health Headlines, the connection between diet and cancer. We’ve heard of so-called good fats in some diets being beneficial to health. A Yale School of Medicine study reveals that the “types” of fat consumed are more important than the amount of fat. Dr. Mandar Muzumdar, associate professor of genetics and internal medicine at Yale School of Medicine, joined Good Morning Connecticut at 9 a.m. to discuss.
- July 20, 2026Source: Yale Cancer Answers (w/ Mandar Muzumdar, MD)
Mandar Muzumdar, MD, discusses the dramatic rise in pancreatic cancer and how his lab is studying whether the types of fats we consume may contribute to the development of cancer, including pancreatic cancer.
- June 07, 2026Source: Daily Mail (with Christian Felipe Ruiz, PhD)
Several types of oil that are often considered to be 'healthy' may actually be fueling the growth of pancreatic cancer tumors, a study suggests.
- April 29, 2026
A new study identifies oleic acid as an unexpected driver of tumor growth and points to omega-3-rich diets as a potential prevention strategy.
- March 12, 2026
Yale scientists identified a hormone that initiates the development and progression of pancreatic cancer in obesity. And it’s not insulin.
- December 01, 2025
Glucagon-like peptide-1 (GLP-1) agonists are showing promise for reducing both cardiometabolic disease prevalence and obesity stigma.
- November 03, 2025Source: WTNH News 8 (with Dr. Jeremy Jacox)
Dr. Jeremy Jacox, a medical oncologist at Yale Cancer Center. Dr. Jacox, joined Good Morning Connecticut at 9 a.m to discuss advances in pancreatic cancer research.
- August 18, 2025
Using new technology, Yale researchers examine cancer progression in single cells to visualize and understand its evolution from pre-cancerous to advanced disease in mouse models. Next steps include human tissue.